

# Single-Center Experience in Five Patients Diagnosed with Lipoid Congenital Adrenal Hyperplasia Due to Steroidogenic Acute Regulatory Protein (STAR) Gene Variants: A Rare Cause of Adrenal Insufficiency

Çetin K et al. STAR-Related Lipoid CAH: Single-Center Insights

Kürşat Çetin<sup>1</sup>, Zeynep Donbaloglu<sup>1</sup>, Yasemin Funda Bahar<sup>1</sup>, Ali Tırtar<sup>1</sup>, Sezin Yakut Uzuner<sup>2</sup>, Mesut Parlak<sup>1</sup>, Hale Tuhan<sup>1</sup>

<sup>1</sup>Akdeniz University Hospital, Department of Pediatric Endocrinology, Antalya, Türkiye

<sup>2</sup>Akdeniz University Hospital, Department of Medical Biology, Antalya, Türkiye

## What is already known on this topic?

Lipoid congenital adrenal hyperplasia represents the most severe and rarest form of congenital adrenal hyperplasia, resulting from mutations in the STAR gene.

The disorder is characterized by impaired adrenal and gonadal steroidogenesis, leading to life-threatening adrenal insufficiency and disorders of sex development.

Timely diagnosis and glucocorticoid/mineralocorticoid replacement therapy are essential to prevent morbidity and mortality.

## What this study adds?

This case series provides detailed clinical, biochemical, radiological, and genetic data from five pediatric patients with genetically confirmed classical LCAH followed at a single tertiary care center.

It describes the presence of three distinct homozygous pathogenic variants in the STAR gene (c.505G>A, c.33del, and c.288G>T), expanding the genotypic spectrum observed in LCAH.

The study reinforces that, despite the severity of the condition, early recognition and appropriate hormone replacement therapy can result in favorable clinical outcomes, including survival without morbidity.

It also underscores the importance of a multidisciplinary and individualized management approach, particularly in patients with disorders of sex development.

## Abstract

Lipoid congenital adrenal hyperplasia (LCAH) is the rarest and most severe form of congenital adrenal hyperplasia (CAH), characterized by impaired adrenal and gonadal steroidogenesis. This case series aims to present our clinical experience with five pediatric patients diagnosed with LCAH due to mutations in the Steroidogenic Acute Regulatory (STAR) gene. Clinical and laboratory data from five patients diagnosed with LCAH and followed at the Pediatric Endocrinology Clinic of Akdeniz University Faculty of Medicine Hospital between January 2020 and May 2025 were retrospectively reviewed. The patients, aged 7 days to 6 months, all exhibited a female phenotype and presented with vomiting and feeding difficulties. Three showed hyperpigmentation. Severe hyponatremia, hyperkalemia, elevated ACTH and renin activity, and low cortisol were observed. Aldosterone and 17-OHP were normal; testosterone and precursors were low. Imaging showed bilateral adrenal lipid infiltration and hyperplasia. Karyotypes included 46,XX (n=3) and 46,XY (n=2). STAR gene mutations identified were c.505G>A, c.33del, and c.288G>T. All received hydrocortisone and fludrocortisone. All survived without morbidity. LCAH is a rare genetic disorder that can present with life-threatening adrenal insufficiency. However, as demonstrated in our cases, early diagnosis and appropriate treatment can lead to excellent outcomes.

**Keywords:** Lipoid congenital adrenal hyperplasia, steroidogenic acute regulatory protein, adrenal insufficiency, disorders of sex development

Assoc. Prof. Hale Tuhan, Akdeniz University Hospital, Department of Pediatric Endocrinology, Antalya, Türkiye

halenvr@hotmail.com

0000-0002-7637-9630

09.10.2025

17.11.2025

**Epub:** 20.11.2025

## Introduction

Lipoid congenital adrenal hyperplasia (LCAH, *OMIM* #201710) is the most severe and rarest form of congenital adrenal hyperplasia (CAH), characterized by impaired synthesis of all adrenal and gonadal steroid hormones (1,2). The most common cause is mutations in the gene encoding the steroidogenic acute regulatory (STAR) protein, which plays a critical role in intracellular cholesterol transport for steroid hormone synthesis.

In classical LCAH, patients typically present with severe adrenal insufficiency within the first few months of life, although symptoms may occasionally appear in later infancy. Common presenting features include vomiting, diarrhea, hyponatremia, hyperkalemia, metabolic acidosis, and hypoglycemia. If left untreated, the condition can be fatal; however, survival into adulthood is possible with early and appropriate mineralocorticoid and glucocorticoid replacement therapy (3,4,5).

Affected 46,XY individuals generally present with female external genitalia due to impaired testicular androgen production (6,7,8). In contrast, 46,XX individuals are born with normal female genitalia and may occasionally experience spontaneous pubertal development. Unlike the adrenal and testicular steroidogenic tissues, the fetal ovary lacks significant steroidogenic enzyme activity and remains unstimulated until puberty. As a result, cholesterol esters do not accumulate during infancy, and ovarian damage is initially avoided (8,9). Consequently, affected 46,XX females may develop secondary sexual characteristics and experience menstrual bleeding. However, over time, progressive accumulation of cholesterol esters in the ovaries leads to the loss of follicular steroidogenic capacity, resulting in anovulatory cycles due to insufficient progesterone synthesis. Eventually, patients develop progressive hypergonadotropic hypogonadism in adolescence or adulthood (10,11).

Defects in either *STAR* or *CYP11A1* (which encodes P450scc) disrupt the initial steps of steroidogenesis, leading to the clinical picture of LCAH (7). Steroid biosynthesis begins with cellular uptake of low-density lipoprotein (LDL)-derived cholesterol (8,10,12). *STAR* mediates

cholesterol transport into the mitochondria, where it is converted into pregnenolone by the P450scc enzyme (2,6,8,10,12,13). The pathophysiology of LCAH has been explained by a “two-hit” model. The first hit involves impaired cholesterol transport due to *STAR* mutations. The second hit results from progressive cellular damage caused by the accumulation of cholesterol esters and toxic cholesterol oxidation products within lipid droplets (6,8,13). Decreased cortisol production weakens negative feedback inhibition on the pituitary gland, leading to increased adrenocorticotrophic hormone (ACTH) secretion. Elevated ACTH levels contribute to hyperpigmentation and adrenal cortical hyperplasia (14).

The human *STAR* gene is located on chromosome 8p11.2 and consists of seven exons (15,16). Most mutations that cause classical LCAH are located in the C-terminal region, between exons 5 and 7, which encodes the *STAR*-associated lipid transfer domain. These mutations usually result in no measurable *STAR* activity and are found in either homozygous or compound heterozygous states involving mutations with similarly reduced function (8). To date, more than 40 pathogenic *STAR* mutations associated with classical LCAH have been described (8,12,17,18). Although *STAR* mutations have been identified in diverse ethnic groups, they are more prevalent in Japan, Korea, and certain isolated populations. In Korea and Japan, the most common variant protein is *p.Gln258X*, accounting for 92.3% and 70% of cases, respectively. The *p.Leu260Pro* mutation is prevalent in Switzerland, *p.Arg182His* in Eastern Saudi Arabia, and *p.Arg182Leu* among Palestinian Arabs (7,8,19,20).

Mutations in *CYP11A1* can also result in a clinical phenotype similar to that of *STAR* mutations, due to P450scc enzyme deficiency, although adrenal hyperplasia is typically absent in these cases (28). While adrenal enlargement is a hallmark of classical LCAH, small adrenals have also been reported and are not pathognomonic (18,21).

A milder form of LCAH, referred to as non-classical or atypical LCAH, is associated with *STAR* mutations that partially preserve protein function (10,22). In such cases, mineralocorticoid secretion is less severely affected, resulting in a milder adrenal insufficiency that manifests later in life. Individuals with a 46, XY karyotype may present with mild disorders of sex development (e.g., hypospadias, micropenis) or even with entirely normal male external genitalia (7,22–25). Adrenal hyperplasia is typically absent in these patients (22,23).

Early diagnosis, appropriate hormone replacement therapy, close monitoring of sex development, and genetic counseling for the family are essential components of the management of this disorder. This case series aims to present our experience in the diagnosis, management, and follow-up of five patients with LCAH caused by mutations in the *STAR* gene.

### Methods

This retrospective, single-center case series included five patients who were diagnosed with LCAH and followed at the Pediatric Endocrinology Department of Akdeniz University Faculty of Medicine Hospital between January 2020 and May 2025. The study was conducted in accordance with the principles of the Declaration of Helsinki and was approved by the Clinical Research Ethics Committee of Akdeniz University Faculty of Medicine (Approval No: KAEK-629, Date: July, 2025). Written informed consent was obtained from the parents of all participants.

Clinical and laboratory data were retrieved retrospectively through a review of the hospital's electronic medical records system. The collected data included demographic information, presenting symptoms, physical examination findings, hormonal profiles, adrenal imaging results, and genetic analyses.

Laboratory parameters assessed in the study included serum electrolytes, bicarbonate, glucose, blood gas pH, serum cortisol, ACTH, aldosterone, plasma renin activity (PRA), 17-hydroxyprogesterone (17-OHP), follicle-stimulating hormone (FSH), luteinizing hormone (LH), total testosterone (T), estradiol (E2), dehydroepiandrosterone sulfate (DHEA-SO<sub>4</sub>), androstenedione, thyroid-stimulating hormone (TSH), free triiodothyronine (fT3), and free thyroxine (fT4).

Chromosomal analysis and pathogenic variants of the *STAR* gene were recorded based on peripheral blood samples. Genetic testing was performed using a multi-gene panel targeting exon regions, analyzed via next-generation sequencing. Variant analysis was conducted using Seq Analysis software (version 15.p) and the Ensembl annotation database. The pathogenicity of the variants was evaluated according to the guidelines of the American College of Medical Genetics and Genomics/Association for Molecular Pathology (ACMG/AMP) (26). Additionally, imaging findings obtained via pelvic ultrasonography (USG) and magnetic resonance imaging (MRI), performed to assess internal genital structures and adrenal morphology, were also included in the study.

### Case reports

**Case 1:** A 49-day-old infant presented with vomiting, diarrhea, and difficulty in feeding. Blood pressure was low and tachycardia was present (Table 1). System examinations were normal, external genitalia were phenotypically female with separate urethral and vaginal openings. Birth and family histories were given in table 2. Laboratory tests revealed hyponatremia (Na: 125 mEq/L), hypochloremia (Cl: 84 mEq/L), hyperkalemia (K: 6.5 mEq/L), and hypoglycemia (38 mg/dL). Complete blood count, renal and liver function tests, infection parameters, and urinalysis were within normal limits. ACTH levels and PRA were markedly elevated. Serum cortisol levels were low, while 17-OHP levels were within the normal range. Hormonal values at admission are summarized in table 3. The patient was admitted to the intensive care unit with a preliminary diagnosis of primary adrenal insufficiency. Treatment included intravenous dextrose bolus, supraphysiological doses of hydrocortisone (100 mg/m<sup>2</sup>/day), sodium-rich intravenous fluid replacement, and fludrocortisone.

Ultrasonography revealed absence of uterus and ovaries, with hyperplastic appearance of the adrenal glands (Table 2). Pelvic MRI showed no Müllerian structures or gonads. Chromosomal/FISH analysis revealed a 46, XY SRY (+) normal male karyotype. Genetic analysis identified a homozygous pathogenic variant *c.288G>T (p.Trp96Cys)* in the *STAR* gene (Table 1).

Multidisciplinary council evaluation led to cystoscopy and vaginotomy, showing a normal urethra and a vaginal length of 3 cm; the cervix was not visualized. Diagnostic laparoscopy revealed absence of uterus and fallopian tubes, with bilateral vas deferens, epididymis, and testes present. Bilateral gonadal biopsy was consistent with immature testicular tissue. A diagnosis of classic LCAH was established. At the last follow-up at 3.5 years old, the patient's height was 94.1 cm [-1.2 standard deviation score (SDS)], weight 14 kg (-0.6 SDS), and body mass index (BMI) 15.8 kg/m<sup>2</sup> (0.26 SDS). The patient remains on hydrocortisone (10 mg/m<sup>2</sup>/day) and fludrocortisone (0.1 mg/day) treatment with stable clinical status and normal electrolytes. Psychological follow-up is ongoing, and the patient continues to be raised as female. Future multidisciplinary assessments are planned.

**Case 2:** A 7-day-old neonate presented with pathological jaundice, vomiting, and difficulty in feeding. Systemic examinations were normal. The external genitalia were phenotypically female. The patient had significant hyperpigmentation compared to family members. Scleral icterus was evident. Blood pressure was low and tachycardia was noted, with other vital signs within normal limits for age (Table 1). Birth and family histories were given in table 2. Phototherapy was planned and the patient was admitted to the neonatal intensive care unit.

Laboratory tests revealed hyponatremia (Na: 126 mEq/L) and hyperkalemia (K: 7 mEq/L). Complete blood count, renal and liver function tests, infection parameters, and urinalysis were normal. Both ACTH and PRA were elevated, while serum cortisol was low and 17-OHP was normal. Additional hormone levels are listed in table 3. Treatment included supraphysiological doses of hydrocortisone, sodium-rich intravenous fluid replacement, and fludrocortisone. Ultrasonography showed uterus and bilateral ovaries, with bilateral adrenal hyperplasia (Table 2). Chromosomal analysis revealed a 46,XX normal female karyotype. Genetic testing identified a homozygous pathogenic variant *c.505G>A (p.Glu169Lys)* in the *STAR* gene, confirming classic LCAH diagnosis (Table 1). Under hydrocortisone (10 mg/m<sup>2</sup>/day) and fludrocortisone (0.1 mg/day) treatment, the patient's skin hyperpigmentation significantly decreased. Clinical condition remained stable with regular follow-up.

**Case 3:** A 2-month-old infant presented to an external center with vomiting and difficulty in feeding and was hospitalized with a preliminary diagnosis of gastroenteritis. The patient appeared severely dehydrated, characterized by dry mucous membranes, prolonged capillary refill

time (4 seconds), and decreased skin turgor due to fluid loss. External genitalia were phenotypically female with double openings and mild posterior labial synechia. The patient exhibited significant hyperpigmentation compared to family members. Birth and family histories were given in table 2. Due to clinical deterioration and resistant hyponatremia (126 mEq/L) and hyperkalemia (8.0 mEq/L), the patient was referred to our center for further evaluation and treatment. Leukocytosis (26,320/mm<sup>3</sup>) and elevated C-reactive protein (48 mg/L, normal: 0–5) were present. Laboratory results showed ACTH and PRA elevated, low cortisol and normal 17-OH progesterone levels. Additional hormonal values are in table 3. On admission to the intensive care unit, the patient presented with hypotension, tachycardia, and fever, while other vital signs were within normal limits for age (Table 1). Treatment included supraphysiological doses of hydrocortisone, sodium-rich intravenous fluid replacement, fludrocortisone, and antibiotic therapy (ampicillin and cefotaxime). Ultrasonography revealed uterus and bilateral ovaries with bilateral adrenal hyperplasia (Table 2). Chromosomal analysis was 46,XX female karyotype. Genetic testing identified a homozygous pathogenic *c.33 deletion (p.Ser12Alafs\*9)* variant in the *STAR* gene, confirming LCAH diagnosis (Table 1). The patient continued hydrocortisone (8 mg/m<sup>2</sup>/day) and fludrocortisone (0.1 mg/day) treatment. Clinical status remained stable with regular follow-up.

**Case 4:** A 10-day-old neonate presented to the emergency department with fever, tachypnea, dyspnea, desaturation, vomiting, and difficulty in feeding. On physical examination, the patient demonstrated significant intercostal retractions, with rales and rhonchi audible on auscultation. The external genitalia were phenotypically female (Table 1). Birth and family histories were given in table 2. The patient was admitted to neonatal intensive care with a diagnosis of congenital pneumonia. Hyponatremia (Na: 124 mEq/L) and hyperkalemia (K: 7.8 mEq/L) were detected. Leukocytosis (24,000/mm<sup>3</sup>) and elevated C-reactive protein (29 mg/dL, normal: 0–5) were present. Another laboratory results showed ACTH and PRA elevated, low cortisol and normal 17-OHP levels. Additional hormonal values are in table 3. Chest X-ray showed bilateral pneumonic infiltrates. The patient developed respiratory failure with severe acidosis on blood gas analysis and received intravenous antibiotics (ampicillin and cefotaxime) and five days of non-invasive mechanical ventilation. Treatment with supraphysiological hydrocortisone, sodium-rich intravenous fluids, and fludrocortisone was started (Table 2). After two weeks of neonatal intensive care, acute phase reactants and electrolyte imbalances improved and the patient was discharged. Ultrasonography showed uterus and bilateral ovaries, and adrenal glands appeared bilaterally hyperplastic. Chromosomal analysis revealed a 46,XX normal female karyotype. Genetic testing showed a homozygous pathogenic *c.505G>A (p.Glu169Lys)* variant in *STAR* gene, confirming LCAH diagnosis (Table 1). The patient's parents of this case were second degree cousins and were related to the father of case 2. Segregation analysis revealed heterozygous variants in both parents. The patient is on hydrocortisone (8 mg/m<sup>2</sup>/day) and fludrocortisone (0.1 mg/day) treatment with normal growth and development at last follow-up at age 5 years. Height was 100.2 cm (0.13 SDS), weight 19 kg (0.16 SDS), BMI 15.6 (0.15). The patient is actively participating in ballet and regular swimming exercises.

**Case 5:** A 6-month-old infant was referred to our center with difficulty in feeding, vomiting, and coma. Blood pressure was low and tachycardia was present, while other vital signs were within age-appropriate limits (Table 1). Systemic examinations were unremarkable. The external genitalia were phenotypically female, with palpable bilateral inguinal gonads, presence of two urogenital openings, and skin hyperpigmentation. Birth and family histories were given in table 2. Laboratory tests showed severe hyponatremia (Na: 95 mEq/L), hyperkalemia (K: 7.2 mEq/L), and hypoglycemia (45 mg/dL). Complete blood count, renal and hepatic function tests, infection markers, and urinalysis were all within normal limits. Laboratory testing revealed markedly elevated ACTH and PRA levels. Serum cortisol was decreased, while 17-OHP levels remained within the normal range. Hormonal values on admission are summarized in table 3. Treatment included intravenous dextrose bolus, supraphysiological hydrocortisone, sodium-rich intravenous fluids, and fludrocortisone. Ultrasonography did not reveal uterus or ovaries; however, bilateral inguinal masses consistent with testes were identified. Adrenal MRI showed bilateral adrenal lipid infiltration and hyperplasia (Table 2). Chromosomal/FISH analysis confirmed 46,XY SRY(+) normal male karyotype. Next-generation sequencing identified a homozygous pathogenic *c.33 deletion (p.Ser12Alafs\*9)* variant in the *STAR* gene (Table 1). Classic LCAH diagnosis was made.

The patient continued mineralocorticoid and glucocorticoid replacement therapy. Segregation analysis revealed heterozygous variants in both parents. The parents of this case and case 3 originate from the same district, suggesting a possible founder effect. Vaginoscopy and cystoscopy revealed intact anatomical structures. Diagnostic laparoscopy showed absence of uterus and ovaries. Bilateral inguinal gonads were visualized; biopsy confirmed immature testicular tissue. No significant hormonal response was observed in the human chorionic gonadotropin (hCG) stimulation test. Multidisciplinary council decided, based on psychological evaluation and family preference, to raise the patient as female. Bilateral gonadectomy was performed at 4 years of age. The patient showed no complications during follow-up, with neurodevelopment appropriate for age. At last follow-up at 4.5 years, height was 103.5 cm (-0.55 SDS), weight 17 kg (-0.13 SDS), BMI 15.8 (0.33 SDS). The patient continues hydrocortisone (12 mg/m<sup>2</sup>/day) and fludrocortisone (0.2 mg/day) treatment and ongoing psychological monitoring.

## Discussion

In this case series, we present the clinical management experience of five pediatric patients diagnosed with LCAH. To contribute to the understanding of the disease's nature, the initial presentations, clinical characteristics, diagnostic processes, and treatment courses of these cases are described in detail.

CAH encompasses a group of autosomal recessive disorders characterized by enzymatic defects in steroidogenesis. LCAH represents the most severe form of CAH due to disruption of the initial step of steroid biosynthesis (7). Since all steps of steroidogenesis are affected, accumulation of steroid hormone precursors does not occur. Therefore, as observed in our study, newborn screening results are usually negative (21). Mutations in the *STAR* gene demonstrate a broad clinical spectrum. Consistent with the literature (8,27), all patients in this case series exhibited vomiting and feeding difficulties; one patient presented with jaundice, another with diarrhea, and one with respiratory distress.

While some affected infants exhibit immediate signs of mineralocorticoid and glucocorticoid deficiency, others may remain asymptomatic for several months (8,28). In this case series, two patients presented during the neonatal period, whereas the remaining three were admitted with adrenal crisis manifestations in early infancy. The latest presenting case (Case 5) survived without hormone replacement therapy until six months of age. Similarly, Bose et al. reported a patient remaining asymptomatic up to six months without hormonal intervention (8). The ability of some LCAH patients to survive for several months without treatment is attributed to the persistence of normal placental steroidogenesis (8). Severe electrolyte disturbances, including hyponatremia, hypochloremia, and hyperkalemia, are commonly observed in patients with classic LCAH, as demonstrated in our patients. Signs of adrenal insufficiency such as hypoglycemia and hypotension may also accompany (8,27). In this case series, all patients were hypotensive at initial presentation, with two exhibiting hypoglycemia. In non-classic LCAH cases, salt loss is either delayed in onset or minimal to absent.

Review of the literature reveals that patients with LCAH, similar to our case series, exhibit elevated plasma ACTH and renin levels, whereas serum cortisol and testosterone levels are variable (1,8). Due to high intrauterine ACTH exposure, hyperpigmentation is an expected finding, though it is not present in all cases (8). Zheng et al. reported hyperpigmentation in 28 of 30 classic LCAH patients (29). Likewise, Boss et al.'s study, which included 15 LCAH cases from 10 countries, documented hyperpigmentation in 13 patients (8). In contrast, only three patients in our series exhibited notable skin hyperpigmentation compared to their parents. This variation may be attributable to inter-individual differences in melanocyte number and structure, as well as genetic and structural factors.

As expected in classic LCAH, two of our patients with male karyotypes presented with fully female external genitalia. On physical examination, additional findings included mild posterior labial synechia in case 1 and palpable bilateral inguinal gonads in case 5. However, in non-classic LCAH patients with a 46, XY karyotype, external genitalia may be completely male-typical or mildly affected (22).

While most LCAH cases are caused by variants in the *STAR* gene, mutations in the *CYP11A1* gene are a much rarer cause (12,30,31). The incidence of this disorder is low, with only approximately 200 cases harboring *STAR* gene variants reported worldwide (32). The *STAR* gene variants identified in our patients have been previously reported as pathogenic in association with LCAH, and all cases were classified as classic LCAH.

The homozygous pathogenic variant *c.288G>T* (*p.Trp96Cys*) found in case 1 has also been described in a Portuguese infant presenting with adrenal crisis at two months, normal female genitalia, and a 46, XY karyotype (33). The *c.505G>A* (*p.Glu169Lys*) variant identified in cases 2 and 4 has been clearly associated with LCAH in the study by Yuksek B et al. (34). The homozygous *c.33 deletion* (*p.Ser12Alafs\*9*) observed in cases 3 and 5 was included among LCAH-related variants in a national study reporting rare primary adrenal insufficiency cases by Güran et al. (35).

In 46,XY patients harboring pathogenic *STAR* variants, impaired fetal testicular steroidogenesis results in normal female external genitalia (8). Since Müllerian structures are absent on pelvic imaging, the diagnosis in 46,XY individuals is more likely (1). Consistently, pelvic USG performed in cases 1 and 5 at presentation did not reveal Müllerian structures. Therefore, even prior to genetic results, *STAR* gene mutation, *CYP11A1* mutation, and P450 oxidoreductase deficiency (POR) were considered highly probable differential diagnoses.

All cases exhibited adrenal enlargement on imaging consistent with classic LCAH. Phadte et al.'s systematic review of 292 cases with classic and non-classic LCAH demonstrated significantly more pronounced adrenal hyperplasia in classic LCAH patients, who also presented with earlier and more severe clinical features. Thus, the degree of adrenal hyperplasia may serve as a valuable marker of disease severity (6).

In this case series, all patients presented with adrenal crisis and were initially managed with an intravenous bolus of hydrocortisone (100 mg/m<sup>2</sup>/day) in combination with sodium-rich intravenous fluid replacement. Maintenance therapy was subsequently initiated. All patients received oral fludrocortisone (100–200 µg/day) along with additional supportive measures when clinically indicated. Similar management strategies for adrenal insufficiency in LCAH have been reported in the literature (27,29).

According to the Diagnosis and Treatment of Primary Adrenal Insufficiency guidelines by Bornstein et al., the recommended initial treatment for pediatric patients presenting with adrenal insufficiency consists of intravenous hydrocortisone at 50–100 mg/m<sup>2</sup>/day, oral fludrocortisone at 100 µg/day, and sodium-rich intravenous fluids containing dextrose (36). Consistent with this, the Turkish Neonatal and Pediatric Endocrinology and Diabetes Societies consensus statement also advises hydrocortisone replacement at 50–100 mg/m<sup>2</sup>/day for infants presenting with adrenal crisis (37).

Zhang et al. described a patient with LCAH who was started on supraphysiological doses of intravenous hydrocortisone, tapered over three days (200 mg/day, 100 mg/day, and 50 mg/day), followed by maintenance therapy with oral prednisone (27). In our series, maintenance therapy consisted of hydrocortisone at 8–12 mg/m<sup>2</sup>/day, divided into three doses, in combination with 100–200 µg/day of fludrocortisone. Similarly, in a report of three Chinese patients with LCAH harboring *STAR* gene variants, supraphysiological doses of intravenous hydrocortisone and sodium-rich intravenous fluids were initially administered, followed by hydrocortisone replacement at 10–14 mg/m<sup>2</sup>/day (7). Çantösun et al. also recommended maintenance hydrocortisone therapy at 8–12 mg/m<sup>2</sup>/day, divided into three doses (38). In a case reported by Bizzarri et al. involving an Italian infant with LCAH, high-dose intravenous hydrocortisone and rehydration were provided until clinical stabilization was achieved, after which maintenance therapy with 16 mg/m<sup>2</sup>/day of hydrocortisone and 100 µg/day of fludrocortisone was continued (1).

## Conclusion

Classic LCAH patients typically present in early infancy with primary adrenal insufficiency symptoms and female external genitalia. Due to the defect occurs at the first step of steroidogenesis, cortisol precursors do not accumulate, making undetected through national CAH screening programs. When identified early and treated with appropriate hormone replacement therapy, patients typically achieve favorable outcomes including no recurrent adrenal crises occurred, appropriate growth, development, and neurodevelopment progression. Genetic counseling for families and comprehensive multidisciplinary monitoring of LCAH patients, especially those with a 46,XY karyotype presenting with disorders of sex development, are essential components in effective disease management.

## Ethics

**Ethics Committee Approval:** The study was conducted in accordance with the principles of the Declaration of Helsinki and was approved by the Clinical Research Ethics Committee of Akdeniz University Faculty of Medicine (Approval No: KAEEK-629, Date: July, 2025).

**Conflicts of Interest:** The authors declare that there is no conflict of interest to disclose.

**Funding:** The authors declare that the study received no funding.

## References

1. Bizzarri C, Pisaneschi E, Mucciolo M, et al. Lipoid congenital adrenal hyperplasia by steroidogenic acute regulatory protein (STAR) gene mutation in an Italian infant: an uncommon cause of adrenal insufficiency. *Ital J Pediatr*. 2017 Jun 20;43(1):57. doi: 10.1186/s13052-017-0371-y. PMID: 28637490; PMCID: PMC5480121.
2. Sahakitrungruang T, Soccio RE, Lang-Muritano M, Walker JM, Achermann JC, Miller WL. Clinical, genetic, and functional characterization of four patients carrying partial loss-of-function mutations in the steroidogenic acute regulatory protein (Star). *J Clin Endocrinol Metab*. 2010 Jul;95(7):3352-9. doi: 10.1210/jc.2010-0437. Epub 2010 May 5. Erratum in: *J Clin Endocrinol Metab*. 2011 Dec;96(12):3908. PMID: 20444910; PMCID: PMC2928910.
3. SANDISON AT. A form of lipoidosis of the adrenal cortex in an infant. *Arch Dis Child*. 1955 Dec;30(154):538-41. doi: 10.1136/adc.30.154.538. PMID: 13275986; PMCID: PMC2011836.
4. Hauffa BP, Miller WL, Grumbach MM, Conte FA, Kaplan SL. Congenital adrenal hyperplasia due to deficient cholesterol side-chain cleavage activity (20, 22-desmolase) in a patient treated for 18 years. *Clin Endocrinol (Oxf)*. 1985 Nov;23(5):481-93. doi: 10.1111/j.1365-2265.1985.tb01107.x. PMID: 3841304.
5. Kirkland RT, Kirkland JL, Johnson CM, Horning MG, Librik L, Clayton GW. Congenital lipoid adrenal hyperplasia in an eight-year-old phenotypic female. *J Clin Endocrinol Metab*. 1973 Mar;36(3):488-96. doi: 10.1210/jcem-36-3-488. PMID: 4685387.
6. Phadte A, Dhole C, Hegishte S, et al. Steroidogenic acute regulatory protein (STAR) deficiency: Our experience and systematic review for phenotype-genotype correlation. *Clin Endocrinol (Oxf)*. 2024 May;100(5):431-440. doi: 10.1111/cen.15032. Epub 2024 Feb 18. PMID: 38368602.
7. Chen H, Zhang Q, Chen R, et al. Lipoid congenital adrenal hyperplasia due to steroid acute regulatory protein (STAR) variants in Three Chinese patients. *J Steroid Biochem Mol Biol*. 2020 Jun;200:105635. doi: 10.1016/j.jsbmb.2020.105635. Epub 2020 Feb 14. PMID: 32068072.
8. Bose HS, Sugawara T, Strauss JF 3rd, Miller WL; International Congenital Lipoid Adrenal Hyperplasia Consortium. The pathophysiology and genetics of congenital lipoid adrenal hyperplasia. *N Engl J Med*. 1996 Dec 19;335(25):1870-8. doi: 10.1056/NEJM199612193352503. PMID: 8948562.
9. Voutilainen R, Miller WL. Developmental expression of genes for the steroidogenic enzymes P450scc (20,22-desmolase), P450c17 (17 alpha-hydroxylase/17,20-lyase), and P450c21 (21-hydroxylase) in the human fetus. *J Clin Endocrinol Metab*. 1986 Nov;63(5):1145-50. doi: 10.1210/jcem-63-5-1145. PMID: 3489728.

10. Miller WL, Bose HS. Early steps in steroidogenesis: intracellular cholesterol trafficking. *J Lipid Res.* 2011 Dec;52(12):2111-2135. doi: 10.1194/jlr.R016675. Epub 2011 Oct 5. PMID: 21976778; PMCID: PMC3283258.
11. Fujieda K, Tajima T, Nakae J, et al. Spontaneous puberty in 46,XX subjects with congenital lipid adrenal hyperplasia. Ovarian steroidogenesis is spared to some extent despite inactivating mutations in the steroidogenic acute regulatory protein (StAR) gene. *J Clin Invest.* 1997 Mar 15;99(6):1265-71. doi: 10.1172/JCI119284. PMID: 9077535; PMCID: PMC507941.
12. Lin D, Sugawara T, Strauss JF 3rd, Clark BJ, et al. Role of steroidogenic acute regulatory protein in adrenal and gonadal steroidogenesis. *Science.* 1995 Mar 24;267(5205):1828-31. doi: 10.1126/science.7892608. PMID: 7892608.
13. Miller WL. Thirty years of StAR gazing. Expanding the universe of the steroidogenic acute regulatory protein. *J Endocrinol.* 2025 Feb 6;264(3):e240310. doi: 10.1530/JOE-24-0310. PMID: 39773408; PMCID: PMC11840834.
14. Michelle M A, Jensen CT, Habra MA, et al. Adrenal cortical hyperplasia: diagnostic workup, subtypes, imaging features and mimics. *Br J Radiol.* 2017 Nov;90(1079):20170330. doi: 10.1259/bjr.20170330. Epub 2017 Jul 14. PMID: 28707538; PMCID: PMC5963387.
15. Miller WL. Congenital lipid adrenal hyperplasia: the human gene knockout for the steroidogenic acute regulatory protein. *J Mol Endocrinol.* 1997 Dec;19(3):227-40. doi: 10.1677/jme.0.0190227. PMID: 9460644.
16. Sugawara T, Lin D, Holt JA, et al. Structure of the human steroidogenic acute regulatory protein (StAR) gene: StAR stimulates mitochondrial cholesterol 27-hydroxylase activity. *Biochemistry.* 1995 Oct 3;34(39):12506-12. doi: 10.1021/bi00039a004. PMID: 7547998.
17. Nakae J, Tajima T, Sugawara T, et al. Analysis of the steroidogenic acute regulatory protein (StAR) gene in Japanese patients with congenital lipid adrenal hyperplasia. *Hum Mol Genet.* 1997 Apr;6(4):571-6. doi: 10.1093/hmg/6.4.571. PMID: 9097960.
18. Bose HS, Sato S, Aisenberg J, Shalev SA, Matsuo N, Miller WL. Mutations in the steroidogenic acute regulatory protein (StAR) in six patients with congenital lipid adrenal hyperplasia. *J Clin Endocrinol Metab.* 2000 Oct;85(10):3636-9. doi: 10.1210/jcem.85.10.6896. PMID: 11061515.
19. Kim JM, Choi JH, Lee JH, et al. High allele frequency of the p.Q258X mutation and identification of a novel mis-splicing mutation in the STAR gene in Korean patients with congenital lipid adrenal hyperplasia. *Eur J Endocrinol.* 2011 Nov;165(5):771-8. doi: 10.1530/EJE-11-0597. Epub 2011 Aug 16. PMID: 21846663.
20. Flück CE, Maret A, Mallet D, et al. A novel mutation L260P of the steroidogenic acute regulatory protein gene in three unrelated patients of Swiss ancestry with congenital lipid adrenal hyperplasia. *J Clin Endocrinol Metab.* 2005 Sep;90(9):5304-8. doi: 10.1210/jc.2005-0874. Epub 2005 Jun 28. PMID: 15985476.
21. Kim CJ, Lin L, Huang N, Quigley CA, et al. Severe combined adrenal and gonadal deficiency caused by novel mutations in the cholesterol side chain cleavage enzyme, P450<sub>sc</sub>. *J Clin Endocrinol Metab.* 2008 Mar;93(3):696-702. doi: 10.1210/jc.2007-2330. Epub 2008 Jan 8. PMID: 18182448; PMCID: PMC2266942.
22. Baker BY, Lin L, Kim CJ, et al. Nonclassic congenital lipid adrenal hyperplasia: a new disorder of the steroidogenic acute regulatory protein with very late presentation and normal male genitalia. *J Clin Endocrinol Metab.* 2006 Dec;91(12):4781-4785. doi: 10.1210/jc.2006-1565. Epub 2006 Sep 12. PMID: 16968793; PMCID: PMC1865081.
23. Metherell LA, Naville D, Halaby G, et al. Nonclassic lipid congenital adrenal hyperplasia masquerading as familial glucocorticoid deficiency. *J Clin Endocrinol Metab.* 2009 Oct;94(10):3865-71. doi: 10.1210/jc.2009-0467. Epub 2009 Sep 22. PMID: 19773404; PMCID: PMC2860769.
24. Miller WL, Auchus RJ. The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. *Endocr Rev.* 2011 Feb;32(1):81-151. doi: 10.1210/er.2010-0013. Epub 2010 Nov 4. Erratum in: *Endocr Rev.* 2011 Aug;32(4):579. PMID: 21051590; PMCID: PMC3365799.
25. Tsai SL, Green J, Metherell LA, et al. Primary Adrenocortical Insufficiency Case Series: Genetic Etiologies More Common than Expected. *Horm Res Paediatr.* 2016;85(1):35-42. doi: 10.1159/000441843. Epub 2015 Dec 10. PMID: 26650942.
26. Richards S, Aziz N, Bale S, et al. Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med.* 2015 May;17(5):405-24. doi: 10.1038/gim.2015.30. Epub 2015 Mar 5. PMID: 25741868; PMCID: PMC4544753.
27. Zhang Y, Song C, Zhang L, Shi L, Zhang Q. STAR gene mutation in a patient with congenital lipid adrenal hyperplasia. *Endokrynol Pol.* 2024;75(3):332-333. doi: 10.5603/ep.99040. Epub 2024 Jun 18. PMID: 38887117.
28. Chen X, Baker BY, Abduljabbar MA, Miller WL. A genetic isolate of congenital lipid adrenal hyperplasia with atypical clinical findings. *J Clin Endocrinol Metab.* 2005 Feb;90(2):835-40. doi: 10.1210/jc.2004-1323. Epub 2004 Nov 16. PMID: 15546900.
29. Zheng WQ, Duan Y, Xiao B, Liang LL, Xia Y, Gong ZW, Sun Y, Zhang HW, Han LS, Wang RF, Yang Y, Zhan X, Yu YG, Gu XF, Qiu WJ. [Clinical and StAR genetic characteristics of 33 children with congenital lipid adrenal hyperplasia]. *Zhonghua Er Ke Za Zhi.* 2022 Oct 2;60(10):1066-1071. Chinese. doi: 10.3760/cma.j.cn112140-20220322-00233. PMID: 36207855.
30. Kim CJ. Congenital lipid adrenal hyperplasia. *Ann Pediatr Endocrinol Metab.* 2014 Dec;19(4):179-83. doi: 10.6065/apem.2014.19.4.179. Epub 2014 Dec 31. PMID: 25654062; PMCID: PMC4316413.
31. Tee MK, Lin D, Sugawara T, et al. T→A transversion 11 bp from a splice acceptor site in the human gene for steroidogenic acute regulatory protein causes congenital lipid adrenal hyperplasia. *Hum Mol Genet.* 1995 Dec;4(12):2299-305. doi: 10.1093/hmg/4.12.2299. PMID: 8634702.
32. Lu W, Zhang T, Zhang L, et al. Clinical characteristics of a male child with non-classic lipid congenital adrenal hyperplasia and literature review. *Front Endocrinol (Lausanne).* 2022 Nov 2;13:947762. doi: 10.3389/fendo.2022.947762. PMID: 36407315; PMCID: PMC9666400.
33. Linhares MI, Silva RB, Mirante A, Cardoso RM. Lipoid congenital adrenal hyperplasia: an uncommon cause of adrenal insufficiency. *Endocrinol Insights.* 2022 July;17(1-2): 67–70. <https://doi.org/10.26497/CC210042>
34. Yüksel B, Kulle AE, Gürbüz F, et al. The novel mutation p.Trp147Arg of the steroidogenic acute regulatory protein causes classic lipid congenital adrenal hyperplasia with adrenal insufficiency and 46,XY disorder of sex development. *Horm Res Paediatr.* 2013;80(3):163-9. doi: 10.1159/000354086. Epub 2013 Aug 1. PMID: 23920000.
35. Guran T, Buonocore F, Saka N, et al. Rare Causes of Primary Adrenal Insufficiency: Genetic and Clinical Characterization of a Large Nationwide Cohort. *J Clin Endocrinol Metab.* 2016 Jan;101(1):284-92. doi: 10.1210/jc.2015-3250. Epub 2015 Nov 2. PMID: 26523528; PMCID: PMC4701852.
36. Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab.* 2016 Feb;101(2):364-89. doi: 10.1210/jc.2015-1710. Epub 2016 Jan 13. PMID: 26760044; PMCID: PMC4880116.
37. Yiğit Ş, Türkmen M, Tuncer O, et al. Neonatal adrenal insufficiency: Turkish Neonatal and Pediatric Endocrinology and Diabetes Societies consensus report. *Türk Pediatri Ars.* 2018 Dec 25;53(Suppl 1):S239-S243. doi: 10.5152/TurkPediatriArs.2018.01822. PMID: 31236037; PMCID: PMC6568299.
38. Çamtosun E, Sangün Ö. Treatment and Prevention of Adrenal Crisis and Family Education. *J Clin Res Pediatr Endocrinol.* 2025 Jan 10;17(Suppl 1):80-92. doi: 10.4274/jcrpe.galenos.2024.2024-6-12-S. Epub 2024 Dec 23. PMID: 39713905; PMCID: PMC11730097.

| <b>Table 1. Genetic and Clinical Characteristics of Patients with Lipoid Congenital Adrenal Hyperplasia</b> |                                                                   |                                                                            |                                                                       |                                                                    |                                                                         |
|-------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|----------------------------------------------------------------------------|-----------------------------------------------------------------------|--------------------------------------------------------------------|-------------------------------------------------------------------------|
|                                                                                                             | <b>Case 1</b>                                                     | <b>Case 2</b>                                                              | <b>Case 3</b>                                                         | <b>Case 4</b>                                                      | <b>Case 5</b>                                                           |
| City of origin                                                                                              | Silopi/Şırnak/<br>Türkiye                                         | Yüreğir/Adana/<br>Türkiye                                                  | Elmalı/Antalya/<br>Türkiye                                            | Yüreğir/Adana/Tü<br>rkiye                                          | Elmalı/Antalya/<br>Türkiye                                              |
| Karyotype                                                                                                   | 46,XY                                                             | 46,XX                                                                      | 46,XX                                                                 | 46,XX                                                              | 46,XY                                                                   |
| <i>STAR</i> gene variant                                                                                    | c.288G>T<br>(p.Trp96Cys)<br>homozygous<br>pathological<br>variant | c.505G>A<br>(p.Glu169Lys)<br>homozygous<br>pathological<br>variant         | c.33 del<br>(p.Ser12Alafs*9)<br>homozygous<br>pathological<br>variant | c.505G>A<br>(p.Glu169Lys)<br>homozygous<br>pathological<br>variant | c.33 del<br>(p.Ser12Alafs*9)<br>homozygous<br>pathological<br>variant   |
| Age of onset (days)                                                                                         | 49                                                                | 7                                                                          | 60                                                                    | 10                                                                 | 180                                                                     |
| <b>Vital signs</b>                                                                                          |                                                                   |                                                                            |                                                                       |                                                                    |                                                                         |
| Blood Pressure<br>(mmHg)                                                                                    | 50/28                                                             | 35/20                                                                      | 55/34                                                                 | 40/25                                                              | 50/30                                                                   |
| Heart Rate (per<br>minute)                                                                                  | 162                                                               | 184                                                                        | 168                                                                   | 190                                                                | 162                                                                     |
| Respiratory Rate<br>(per minute)                                                                            | 38                                                                | 44                                                                         | 40                                                                    | 68                                                                 | 30                                                                      |
| Oxygen Saturation<br>(%)                                                                                    | 99                                                                | 98                                                                         | 98                                                                    | 85                                                                 | 100                                                                     |
| Temperature (C°)                                                                                            | 36.5                                                              | 36.6                                                                       | 38.6                                                                  | 38.2                                                               | 36.6                                                                    |
| Clinical findings                                                                                           | Inadequate oral<br>intake, vomiting,<br>diarrhea                  | Skin<br>hyperpigmentation,<br>inadequate oral intake,<br>vomiting, icterus | Skin<br>hyperpigmentation,<br>inadequate oral intake,<br>vomiting     | Inadequate oral<br>intake, vomiting,<br>dyspnea,<br>tachypnea      | Skin<br>hyperpigmentation,<br>inadequate oral intake,<br>vomiting, coma |
| Genital<br>examination                                                                                      | Normal female                                                     | Female genitalia,<br>mild posterior labial<br>synechia                     | Normal female                                                         | Normal female                                                      | Female genitalia,<br>bilateral inguinal<br>palpable gonads              |
| EGS                                                                                                         | EGS: 0                                                            | EGS: 1.5                                                                   | EGS: 0                                                                | EGS: 0                                                             | EGS: 1                                                                  |
| STAR: Steroidogenic Acute Regulatory; EGS: External Genitalia Scores                                        |                                                                   |                                                                            |                                                                       |                                                                    |                                                                         |

| <b>Table 2. Perinatal History, Family Background, Imaging Findings, and Treatment Characteristics in Patients with Lipoid Congenital Adrenal Hyperplasia</b> |               |               |               |               |               |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------|---------------|---------------|---------------|---------------|
|                                                                                                                                                              | <b>Case 1</b> | <b>Case 2</b> | <b>Case 3</b> | <b>Case 4</b> | <b>Case 5</b> |
| <b>Perinatal history</b>                                                                                                                                     |               |               |               |               |               |
| Birth weight (g, percentile)                                                                                                                                 | 3750 (85th)   | 3000 (40th)   | 2800 (45th)   | 3050 (25th)   | 3530 (45th)   |
| Birth length (cm, percentile)                                                                                                                                | 51 (75th)     | 49 (50th)     | 49 (65th)     | 50 (50th)     | 51 (50th)     |
| Head circumference (cm,<br>percentile)                                                                                                                       | 36 (85th)     | 34 (40th)     | 34 (60th)     | 35 (60th)     | 35 (45th)     |
| Gestational Age (w)                                                                                                                                          | 38            | 38            | 37            | 40            | 41            |
| Mode of Delivery                                                                                                                                             | NSVY          | C/S           | C/S           | NSVY          | NSVY          |
| Newborn CAH Screening<br>(Heel Prick)                                                                                                                        | Normal        | Normal        | Normal        | Normal        | Normal        |
| <b>Family History</b>                                                                                                                                        |               |               |               |               |               |

|                        |                                                         |                                                         |                                                        |                                                        |                                                         |
|------------------------|---------------------------------------------------------|---------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|---------------------------------------------------------|
| Parental Consanguinity | No                                                      | No                                                      | No                                                     | second-degree cousins                                  | second-degree cousins                                   |
| CAH/SIDS/DSD           | None                                                    | +/-/-                                                   | None                                                   | +/-/-                                                  | None                                                    |
| Adrenal imaging        | Adrenolipoid hyperplasia                                | Adrenolipoid hyperplasia                                | Adrenolipoid hyperplasia                               | Adrenolipoid hyperplasia                               | Adrenolipoid hyperplasia                                |
| Maintenance treatment  | Hydrocortisone (10 mg/m2/d), fludrocortisone (0.1 mg/d) | Hydrocortisone (10 mg/m2/d), fludrocortisone (0.1 mg/d) | Hydrocortisone (8 mg/m2/d), fludrocortisone (0.1 mg/d) | Hydrocortisone (8 mg/m2/d), fludrocortisone (0.1 mg/d) | Hydrocortisone (12 mg/m2/d), fludrocortisone (0.2 mg/d) |

CAH: congenital adrenal hyperlasia; SIDS: sudden infant death syndrome; DSD: disorders of sex development; g: gram; cm: centimeters; w: weeks; d: day; NSV: normal spontaneous vaginal delivery; C/S: cesarean section; mg: milligram; m2: square meter; +: present; -: absent

| <b>Table 3. Biochemical Results and Hormonal Profiles of Patients with Lipoid Congenital Adrenal Hyperplasia</b> |               |               |               |                 |               |                                   |
|------------------------------------------------------------------------------------------------------------------|---------------|---------------|---------------|-----------------|---------------|-----------------------------------|
| <b>Laboratory test results</b>                                                                                   | <b>Case 1</b> | <b>Case 2</b> | <b>Case 3</b> | <b>- Case 4</b> | <b>Case 5</b> | <b>Reference range</b>            |
| Serum Sodium (mmol/L)                                                                                            | 125           | 126           | 126           | 124             | 95            | 135-145                           |
| Serum Potassium (mmol/L)                                                                                         | 6.5           | 7.0           | 8.0           | 7.8             | 7.2           | 3.5-5.1                           |
| Serum Chloride (mmol/L)                                                                                          | 84            | 88            | 90            | 85              | 68            | 98-107                            |
| Serum Glucose (mg/dl)                                                                                            | 38            | 70            | 82            | 76              | 45            | 60-100                            |
| <b>Hormones</b>                                                                                                  |               |               |               |                 |               |                                   |
| ACTH (ng/L)                                                                                                      | 1588          | > 2000        | > 2000        | > 2000          | > 2000        | 7.2–63.3                          |
| Cortisol (ug/dL)                                                                                                 | 0.31          | 0.63          | 1.0           | 0.89            | 0.63          | Newborn: 2.0-11<br>Infant: 2.8-23 |
| PRA (ng/mL/h)                                                                                                    | 11            | 18.7          | 10.9          | 10.7            | 7.7           | 0.1–6.5                           |
| 17-OHP (ng/ml)                                                                                                   | 0.1           | 0.23          | 0.13          | 0.80            | 0.17          | 0.10–1.78                         |
| Aldosterone (ng/dl)                                                                                              | 4.2           | 11.9          | 6.5           | 13.1            | 6.7           | 7-30                              |
| Testosterone (ng/dL)                                                                                             | < 0.03        | < 0.03        | < 0.03        | < 0.03          | < 0.03        | 0.14-0.76                         |
| Androstenedion (ng/mL)                                                                                           | < 0.02        | 1.25          | 0.26          | 0.30            | < 0.02        | 0.3-3.2                           |
| DHEA-SO4 (ug/dL)                                                                                                 | < 0.2         | 1.1           | 5.28          | 4.83            | < 0.2         | 31.6-431                          |
| TSH (mIU/L)                                                                                                      | 2.43          | 3.70          | 3.22          | 2.85            | 3.64          | 0.72-11                           |
| fT3 (ng/L)                                                                                                       | 3.42          | 3.45          | 3.82          | 2.96            | 3.52          | 1.95-6.04                         |
| fT4 (ng/dL)                                                                                                      | 1.66          | 1.21          | 1.53          | 1.18            | 1.34          | 0.89-2.2                          |
| LH (IU/liter)                                                                                                    | 1.25          | 1.34          | 1.94          | 1.26            | 1.17          |                                   |
| FSH (IU/liter)                                                                                                   | 9.2           | 9.5           | 7.87          | 6.83            | 4.27          |                                   |
| Estradiol                                                                                                        | < 5           | < 5           | < 5           | < 5             | < 5           |                                   |

ACTH: adrenocorticotrophic hormone; PRA: plasma renin activity; 17-OHP:17-hydroxylprogesterone; DHEA-SO4: dehydroepiandrosterones sulfate; TSH: thyroid stimulating hormone; fT3: free triiodothyronine; fT4: free thyroxine.